ARS Pharmaceuticals Inc
SPRY16.090USD
-1.360-7.79%
종가 07/01, 16:00（ET）시세는 15분 지연됩니다
1.58B시가총액
손실P/E TTM
자세한 내용은 ARS Pharmaceuticals Inc 회사
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
회사 정보
종목 코드 SPRY
회사 이름ARS Pharmaceuticals Inc
상장일Dec 04, 2020
설립일2016
CEOMr. Richard E. Lowenthal
직원 수155
유형Ordinary Share
회계 연도 종료Dec 04
주소11682 El Camino Real, Suite 120
도시SAN DIEGO
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호92130
전화18587719307
웹사이트https://ars-pharma.com/
종목 코드 SPRY
상장일Dec 04, 2020
설립일2016
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Rajeev Dadoo, Ph.D.
Dr. Rajeev Dadoo, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Pratik Shah, Ph.D.
Dr. Pratik Shah, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
6.83M
-14.34%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
4.57M
-10.85%
Mr. Justin Chakma
Mr. Justin Chakma
Chief Business Officer
Chief Business Officer
136.38K
--
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.33%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Mon, Jun 2
마지막 업데이트: Mon, Jun 2
주주
주주 유형
주주
주주
비율
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
주주
주주
비율
RA Capital Management, LP
11.06%
Deerfield Management Company, L.P.
10.71%
OrbiMed Advisors, LLC
8.44%
Lowenthal (Richard E)
6.95%
Pratik Shah Living Trust
4.91%
Other
57.93%
주주 유형
주주
비율
Investment Advisor/Hedge Fund
20.71%
Hedge Fund
19.64%
Venture Capital
15.20%
Investment Advisor
13.88%
Individual Investor
12.16%
Private Equity
8.44%
Corporation
4.91%
Research Firm
2.18%
Pension Fund
0.27%
Other
2.62%
기관 주식 보유
마지막 업데이트: 16 hours ago
마지막 업데이트: 16 hours ago
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
361
95.98M
97.72%
-8.84M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
2023Q3
283
95.82M
104.35%
+1.21M
2023Q2
278
88.26M
96.94%
-730.20K
2023Q1
271
88.79M
98.08%
+1.91M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
RA Capital Management, LP
10.86M
11.06%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
10.51M
10.71%
--
--
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.44%
--
--
Mar 31, 2025
Lowenthal (Richard E)
6.83M
6.95%
-1.14M
-14.34%
Mar 31, 2025
Pratik Shah Living Trust
4.82M
4.91%
--
--
Mar 31, 2025
Tanimoto (Sarina)
4.57M
4.66%
-556.66K
-10.85%
Mar 31, 2025
SR One Capital Management, LP
4.01M
4.09%
--
--
Mar 31, 2025
AllianceBernstein L.P.
3.92M
3.99%
+42.07K
+1.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.88M
3.95%
-275.85K
-6.63%
Mar 31, 2025
The Vanguard Group, Inc.
3.48M
3.54%
+23.34K
+0.68%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Fri, Jun 6
마지막 업데이트: Fri, Jun 6
이름
비율
First Trust Small Cap Growth AlphaDEX Fund
0.6%
Janus Henderson Small Cap Growth Alpha ETF
0.39%
First Trust Small Cap Core Alphadex Fund
0.29%
SPDR S&P Biotech ETF
0.24%
iShares Micro-Cap ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
First Trust Multicap Growth Alphadex Fund
0.11%
Principal U.S. Small-Cap ETF
0.11%
더 보기
First Trust Small Cap Growth AlphaDEX Fund
비율0.6%
Janus Henderson Small Cap Growth Alpha ETF
비율0.39%
First Trust Small Cap Core Alphadex Fund
비율0.29%
SPDR S&P Biotech ETF
비율0.24%
iShares Micro-Cap ETF
비율0.16%
Direxion Daily S&P Biotech Bull 3X Shares
비율0.16%
ProShares Ultra Nasdaq Biotechnology
비율0.14%
Invesco Nasdaq Biotechnology ETF
비율0.14%
First Trust Multicap Growth Alphadex Fund
비율0.11%
Principal U.S. Small-Cap ETF
비율0.11%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
